The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.
The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.
Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.
The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.
AstraZeneca, GlaxoSmithKline, Takeda, Pfizer and Eli Lilly are among seven drugmakers making their discarded molecules available in what amounts to a molecule library.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.
The FDA greenlighted the drug for three cancers.
A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.
Executives urge analysts to focus on the company's long-term potential.
The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union
It's the second for this cancer drug in two weeks.
The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.
The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.
HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.
Dr. Joep Lange was en route to the International AIDS Conference in Melbourne, Australia.
He started the Dose of Digital blog in 2008, then left healthcare. Now, after more than two years away, Jonathan Richman says he's back in the business.
Less-frequent dosing and competitive pricing could spur a shift in market share among products that treat the hereditary blood disorder.
Haymarket Media launched the site PsychiatryAdvisor.com today.
Parent Project Muscular Dystrophy (PPMD) and allied stakeholders recently gave FDA the first patient advocacy-initiated guidance for a rare disease to help accelerate development and review of potential therapies for Duchenne muscular dystrophy.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Treasury Secretary Jacob Lew is urging lawmakers to prevent companies from "effectively renouncing their citizenship to get out of paying taxes," while also benefitting from the US-funded infrastructure.
Researchers found that patients were more accurate when doling out medication measured in milliliters as opposed to teaspoons or tablespoons.
Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.
Researchers at the Brigham and Women's Hospital found that continuity in color and shape have a significant impact on whether patients stick with a prescription regimen.
Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.
Hepatitis C medication Olysio was a star, but the company cautions competition is coming.
The FDA granted Priority Review for consideration of Avastin for some cervical-cancer patients.
An advocacy group alleges that Shire's decision to ignore the US Fabry disease market was the result of a backroom deal with Sanofi.
Novartis and the nonprofit Banner Alzheimer's Institutes are testing a theory that treating healthy patients could prevent or delay Alzheimer's disease.
Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.
Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.
Cyramza patients had more favorable overall survival rates than placebo patients, but the differences were not statistically significant.
German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.
The House Energy and Commerce Committee is putting two health-related bills to vote Monday. One covers new sunscreen ingredients, the other muscular dystrophy research.
In the latest chapter in the Sovaldi pricing saga, Senators Ron Wyden and Charles Grassley urge Gilead to clarify Sovaldi sticker shock.
Bristol-Myers Squibb is moving forward with its FDA filing of PD-1 Opdivo (formerly known as nivolumab) for patients with advanced melanoma who have been previously treated with the BMS drug Yervoy.
Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.
The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.
Allergan will implement company-wide cost-cutting maneuvers, Bloomberg reports, to keep Valeant at bay.
Prices for some generics are rising, thanks to limited competition.
UnitedHealthcare finds drug costs more than doubled.
Servier and Teva have been fined for keeping a generic heart medication off the market.
The FDA says the OTC remedy maker's online behavior—including Liking customer Facebook posts—has put the company's drugs in unapproved drug territory.
Two weeks after its $46-billion bid was shot down, AbbVie has revised its offer in hopes of opening up negotiations with Shire.
The drugmaker received a notice from the advertising watchdog over promotion of hep. B treatment Viread in a sponsored link on Google AdWords.
Purdue Pharma expects the FDA to vote yea or nay on the drug by October.
The companies will develop Lilly's glucokinase activator LY2608204.
The drugstore chain will no longer sell Sudafed in West Virginia.
It's the generics maker's second recall of 2014.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
The Wall Street Journal notes that a new study on testosterone therapy has some weaknesses, including its sole focus on men who received injections—leaving out pills, patches and gels.
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
The head of evidence-based medicine at Milan's health authority Alberto Donzelli has pulled down criticism of Merck's cholesterol drug ezetimibe from his website, after the drugmaker sent two cease-and-desist letters.
In what amounts to a sudden about face, CMS wants to delete the Sunshine rule's exclusion for continuing medical education.
Editorial says risk is small, researchers say it could be clinically relevant.
Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.
The European Commission is rolling out a verified-account tag it hopes will connect Internet users with trustworthy drug sources.
The solution: talk to patients.
The consumer-facing edition of The Merck Manual Go-To Home Guide for Symptoms is being released as a mobile app.
French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
Health insurers and pharmacies signed a letter asking the FDA to require biosimilars and branded biologics to share the same name.
Boehringer Ingelheim's experimental idiopathic pulmonary fibrosis treatment nintedanib is also an orphan drug.
The Indian Pharmaceutical Alliance makes a bid for legislators' attention.
The American College of Physicians says most women do not need an annual pelvic exam. The American College of Obstetrics and Gynecologists disagrees.
The website is a joint effort between Merck and The Lancet.
The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.
Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.
Researchers from Boston Children's Hospital, Harvard Medical School and Brigham and Women's Hospital are offering a bit of internet advice for the Food and Drug Administration: do more.
The FDA approved the inhaled insulin last week.
The regulator wants men to be part of breast cancer clinical trials.
The networking site's emotion experiment rankles some in the science and political communities.
Novartis no longer has a lock on the Diovan market: the FDA approved Ranbaxy's generic, which will be made in the US.
Following two comprehensive rounds of scoring by more than 100 independent industry judges, the results are in for the MM&M Awards 2014. Here are the five finalists for each of the 31 categories
An internal probe for a controversial ad for hypertension drug Blopress was released by Takeda, but the report is in Japanese.
Pennsylvania drugmaker Auxilium will merge with Vancouver-based biotech QLT to lower its corporate tax rate.
FDA says it will fast track the blood-thinner antidote, designed to thwart runaway bleeding.
IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.
The firm ended the Phase III trial for its ballyhooed immunotherapy, which showed superior survival compared to chemo in advanced melanoma.
Certain claims of the patents protecting the ADHD drug were both infringed and valid, a court ruled, giving Shire a boost as it contends with a takeover bid by AbbVie.
The firm said it expects to more than double its revenue within the decade, as the surging incidence of diabetes expands demand for its products.
EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.
Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.
The regulator is issuing draft guidance to address gene therapies.
An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
Dublin-based Shire is urging shareholders to back independence and ignore AbbVie's $46.4 billion bid.
BI says there is no unmet need for faldaprevir.
Four months after announcing a review of low-testosterone treatments for risk of heart attack and stroke, the regulator expanded the classes' warning label to include a general risk of blood clots.
GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.